Clinical Trial Update: Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating efanesoctocog alfa for prophylaxis in Hemophilia A patients with synovial hypertrophy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Efanesoctocog alfa (efanesoctocog alfa)

Snippet

Sponsor: Sanofi | Conditions: Factor VIII Deficiency | Phase 4 | Status: RECRUITING